Identifying Growth Hormone Markers in Short Children
Author Information
Author(s): Gunnel Hellgren, Björn Andersson, Andreas FM Nierop, Jovanna Dahlgren, Ze'ev Hochberg, Kerstin Albertsson-Wikland
Primary Institution: Göteborg Pediatric Growth Research Center, University of Gothenburg
Hypothesis
Can a proteomic approach identify biomarkers that predict growth hormone treatment response in children with idiopathic short stature?
Conclusion
The study found that transthyretin and apolipoprotein A-II may serve as biomarkers to predict growth response to growth hormone treatment in short prepubertal children.
Supporting Evidence
- 82% of children were correctly classified as high or low responders to growth hormone treatment based on protein peak changes.
- Transthyretin levels decreased in high responders and increased in low responders during treatment.
- Apolipoprotein A-II levels decreased in high responders but remained unchanged in low responders.
Takeaway
Researchers looked at blood samples from short children to find out which proteins could help predict how well they would grow with hormone treatment.
Methodology
The study analyzed serum protein expression profiles before and after one year of growth hormone treatment using SELDI-TOF mass spectrometry.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the handling of serum samples.
Limitations
The study was limited to Caucasian children and excluded those with chronic diseases or dysmorphic syndromes.
Participant Demographics
All participants were prepubertal children with idiopathic short stature, primarily of Caucasian descent.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website